u/naomi_erdogan

Agreed. The 503A versus 503B distinction changes who is allowed to make what, and almost every confused thread here starts by ignoring it.

Are you eating in the couple of hours before you sleep?

How long has it been going on for now?

Nothing in this thread is medical advice, including this comment. I am describing a mechanism, not telling anybody what to do about their own week.

Mine settled at week 56 and has not come back since, across two more steps.

Agreed, with the caveat that "usually settles" is not "always settles" and the exceptions should still get asked about properly.

the escalation is where most of the reported trouble sits

not approved anywhere, which is the single most important fact in this board

Small fix — three receptors, not two. GLP-1, GIP and glucagon, and the third one is the reason this compound gets its own board.

Small fix — those two prices are for different pack sizes, which accounts for most of the gap.

The ranking functions are published: the hot ordering combines score magnitude with age, and the controversial ordering weights total volume by the balance between up and down votes. Both are reproducible from the numbers on each submission.

Pushback: you changed the dose, the meal timing and the training in the same fortnight, so the attribution is guesswork.

Not convinced. A payment window that closed is a payment window, not evidence of intent.

Correcting myself upthread: the criterion I quoted was updated for this year.

That shortage notice was national and does not apply where the question is coming from.

Held the dose for an extra six weeks instead of stepping. The fatigue settled and I lost the same amount anyway.

Correction: TRIUMPH is the phase 3 programme. The number you are quoting is from the phase 2 readout, which is a different trial.

This. A bad fortnight after a step is expected. A bad quarter is a reason to talk to somebody who knows your history.

Correction: that domain is one character different from the one you posted, which is rather the point of this thread.

comparing reta phase 2 to sema phase 3 is comparing different things

the TRIUMPH programme is still running, so anything definitive is premature

Increases in heart rate have been reported across this receptor class. The magnitude and clinical significance are exactly what phase 3 is powered to establish.

Disagree — a 503B being registered does not make its preparations equivalent to an approved product. Different regulatory category entirely.

Same read. The energy-expenditure mechanism is the interesting bit and it is not established in humans at scale.

That symptom is not the one being described upthread. Two different things with similar names and the answers are not interchangeable.

a shop that will only talk off-platform has told you something

Adding the practical version: buy small from anyone new, test it, then decide.

eating slower does more than most of the supplements people recommend

the glucagon component is why the metabolic story reads differently

Disagree. "More receptors means more effect" is not how any of this works and the trial data does not support the linear story.